Christopher J. Sweeney

2000–2025 年に発表

165
論文数
26,655
被引用数
87
h 指数
158
i10 指数

被引用数

Christopher J. Sweeney の年別被引用数2001 年: 被引用 7 件2002 年: 被引用 27 件2003 年: 被引用 45 件2004 年: 被引用 54 件2005 年: 被引用 57 件2006 年: 被引用 70 件2007 年: 被引用 61 件2008 年: 被引用 61 件2009 年: 被引用 62 件2010 年: 被引用 70 件2011 年: 被引用 60 件2012 年: 被引用 71 件2013 年: 被引用 73 件2014 年: 被引用 95 件2015 年: 被引用 116 件2016 年: 被引用 128 件2017 年: 被引用 155 件2018 年: 被引用 213 件2019 年: 被引用 788 件2020 年: 被引用 944 件2021 年: 被引用 1,063 件2022 年: 被引用 879 件2023 年: 被引用 722 件2024 年: 被引用 1,262 件2025 年: 被引用 564 件2026 年: 被引用 22 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,705 件、この内訳の 24.7%中国: 引用元論文 885 件、この内訳の 8.1%イギリス: 引用元論文 728 件、この内訳の 6.6%イタリア: 引用元論文 646 件、この内訳の 5.9%ドイツ: 引用元論文 579 件、この内訳の 5.3%カナダ: 引用元論文 542 件、この内訳の 5%フランス: 引用元論文 466 件、この内訳の 4.3%スペイン: 引用元論文 378 件、この内訳の 3.5%日本: 引用元論文 365 件、この内訳の 3.3%オーストラリア: 引用元論文 358 件、この内訳の 3.3%スイス: 引用元論文 309 件、この内訳の 2.8%オランダ: 引用元論文 297 件、この内訳の 2.7%
0%24.7%その他 24.5%

分野

  • Medicine67.7%
  • Biochemistry, Genetics and Molecular Biology23.5%
  • Immunology and Microbiology2.3%
  • Agricultural and Biological Sciences1.2%
  • Computer Science1.2%
  • Engineering0.7%
  • その他3.4%

トピック

  • Prostate Cancer Treatment and Research12.8%
  • Prostate Cancer Diagnosis and Treatment7.6%
  • Radiopharmaceutical Chemistry and Applications3.1%
  • Cancer, Lipids, and Metabolism2.7%
  • Cancer Immunotherapy and Biomarkers2.4%
  • Cancer Genomics and Diagnostics2.4%
  • その他69%

共著者

全論文

検索で開く
  1. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 2,835

  2. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Zielinski, Christopher J. Sweeney - New England Journal of Medicine 2019 被引用: 1,593

  3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 被引用: 1,106

  4. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

    著者: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 被引用: 564

  5. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 406

  6. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2021 被引用: 329

  7. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 242

  8. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ian D. Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle R. Cronk, Katharine Cuff, Ian D. Davis, Anthony Dowling, Mark Frydenberg, M. C. George, Lisa G. Horvath, Elizabeth Hovey, Anthony M. Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence E. Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Martin R. Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, H. E. A. Campbell, Kim Chi, Joseph L. Chin, E. Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sebastién J. Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Éric Vigneault, Paweł Zalewski, John McCaffrey, Ray McDermott, Patrick G. Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile M. O’Donnell, Dearbhaile O'Donnell, Peter C.C. Fong, Alvin Tan, Simon Chowdhury ほか 13 名 - The Lancet Oncology 2023 被引用: 188

  9. EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Housheng Hansen He, Matthew L. Freedman, Steven P. Balk, Massimo Loda, David P. Labbé, Brian M. Olson, Leigh Ellis - Nature Cancer 2021 被引用: 241

  10. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki ほか 18 名 - European Journal of Cancer 2023 被引用: 157

  11. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    著者: , , , , , , , , , , , - Journal of Clinical Oncology 2018 被引用: 505

  12. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 434

  13. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

    著者: , , , , , , , , , , - European Urology 2018 被引用: 269

  14. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki ほか 18 名 - European Urology 2022 被引用: 118

  15. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer

    著者: , , , , , , , , , , , , , , - JAMA Oncology 2023 被引用: 121

  16. Next generation radiotheranostics promoting precision medicine

    著者: , , , , , , , - Annals of Oncology 2023 被引用: 69

  17. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David J. Vaughn, Cora N. Sternberg, Axel Heidenreich, J. Beyer - Journal of Clinical Oncology 2021 被引用: 238

  18. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gero Kramer, Chris Logothetis, Fernando Cotait Maluf, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R. Padhani, Chris Parker, Colin C. Pritchard, Mack Roach, Mark A. Rubin, Charles J. Ryan, Fred Saad, Oliver Sartor, Howard I. Scher, Avishay Sella, Neal D. Shore, Matthew R. Smith, Howard R. Soule, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher J. Sweeney, Matthew R. Sydes, Ian F. Tannock, Bertrand Tombal, R. Valdagni, Thomas Wiegel, Aurelius Omlin - European Urology 2017 被引用: 643

  19. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

    著者: , , , , , , , , , , , , , , , , - European Urology 2019 被引用: 320

  20. Current treatment strategies for advanced prostate cancer

    著者: , , , , , - International Journal of Urology 2017 被引用: 247

  21. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 89

  22. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

    著者: , , , , , , , , , , , , , , , , , , , - European Urology 2018 被引用: 247

  23. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

    著者: , , , , , , , , , , , , , - Cancer Discovery 2021 被引用: 101

  24. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 67